S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Quanterix Stock Forecast, Price & News

+4.19 (+6.63 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $67.37
50-Day Range
MA: $77.19
52-Week Range
Now: $67.37
Volume727,235 shs
Average Volume481,708 shs
Market Capitalization$2.42 billion
P/E RatioN/A
Dividend YieldN/A
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Quanterix logo


Preview: Quanterix's Earnings - Yahoo Finance
March 2, 2021 |  finance.yahoo.com
Preview: Quanterix's Earnings
March 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:QTRX
Year FoundedN/A



Sales & Book Value

Annual Sales$56.73 million
Book Value$4.59 per share


Net Income$-40,800,000.00


Market Cap$2.42 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.22 out of 5 stars

Medical Sector

860th out of 1,968 stocks

Analytical Instruments Industry

16th out of 29 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+4.19 (+6.63 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Quanterix (NASDAQ:QTRX) Frequently Asked Questions

Is Quanterix a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Quanterix stock.
View analyst ratings for Quanterix
or view top-rated stocks.

What stocks does MarketBeat like better than Quanterix?

Wall Street analysts have given Quanterix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quanterix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Quanterix's next earnings date?

Quanterix is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Quanterix

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) released its quarterly earnings data on Monday, March, 1st. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. Quanterix had a negative trailing twelve-month return on equity of 22.37% and a negative net margin of 41.69%.
View Quanterix's earnings history

How has Quanterix's stock been impacted by Coronavirus?

Quanterix's stock was trading at $18.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QTRX shares have increased by 264.0% and is now trading at $67.37.
View which stocks have been most impacted by COVID-19

What guidance has Quanterix issued on next quarter's earnings?

Quanterix issued an update on its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20-22 million, compared to the consensus revenue estimate of $21.7 million.

What price target have analysts set for QTRX?

3 equities research analysts have issued 1 year target prices for Quanterix's shares. Their forecasts range from $40.00 to $90.00. On average, they expect Quanterix's share price to reach $71.67 in the next year. This suggests a possible upside of 6.4% from the stock's current price.
View analysts' price targets for Quanterix
or view top-rated stocks among Wall Street analysts.

Who are Quanterix's key executives?

Quanterix's management team includes the following people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 59, Pay $1.31M)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 68, Pay $41k)
  • Mr. Amol Chaubal, Chief Financial Officer (Age 45, Pay $501.87k)
  • Mr. John J. Fry, Gen. Counsel & Corp. Sec. (Age 60, Pay $465k)
  • Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 62)
  • Mr. William Geist, Chief Operating Officer
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 50)
  • David Panzerella, VP of Sales
  • Dr. Mark T. Roskey, Sr. VP of Commercial & Accelerator (Age 61)
  • Dr. Dawn R. Mattoon Ph.D., Sr. VP of Research Products (Age 48)

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

When did Quanterix IPO?

(QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.50%), Frontier Capital Management Co. LLC (4.74%), Price T Rowe Associates Inc. MD (3.58%), Ashford Capital Management Inc. (1.30%), Tikvah Management LLC (1.21%) and Monashee Investment Management LLC (1.26%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix

Which major investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Next Century Growth Investors LLC, Royce & Associates LP, Assenagon Asset Management S.A., Northern Trust Corp, and Bank of New York Mellon Corp. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix
or view top insider-selling stocks.

Which major investors are buying Quanterix stock?

QTRX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Clearbridge Investments LLC, Monashee Investment Management LLC, Caas Capital Management LP, Laurion Capital Management LP, First Trust Advisors LP, Lord Abbett & CO. LLC, and ExodusPoint Capital Management LP.
View insider buying and selling activity for Quanterix
or or view top insider-buying stocks.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $67.37.

How much money does Quanterix make?

Quanterix has a market capitalization of $2.42 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Quanterix have?

Quanterix employs 248 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is www.quanterix.com.

Where are Quanterix's headquarters?

Quanterix is headquartered at 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821.

How can I contact Quanterix?

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.